期刊
FUTURE MICROBIOLOGY
卷 6, 期 12, 页码 1415-1427出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FMB.11.128
关键词
AmpC; AmpG; AmpR; antibiotic resistance; beta-lactam; beta-lactamase; cystic fibrosis; FtsZ; NagZ; Pseudomonas aeruginosa
类别
资金
- Canadian Institutes of Health Research
- Cystic Fibrosis Canada
- The Manitoba Health Research Council
- Ministerio de Ciencia e Innovacion, Institut de Salud Carlos III
- European Development Regional Fund ERDF
- Spanish Network for Research in Infectious Diseases [REIPI RD06/0008, PS09/00033]
A major cause of the clinical failure of broad-spectrum beta-lactam antibiotics against Pseudomonas aeruginosa and many Enterobacteriaceae species are chromosomal mutations that lead to the hyperproduction of AmpC beta-lactamase. These mutations typically affect proteins within the peptidoglycan (PG) recycling pathway, as well as proteins that are modulated by metabolic intermediates of this pathway. Blocking PG recycling and associated sensing mechanisms with small-molecule inhibitors holds promise as a strategy for overcoming AmpC-mediated resistance that results from the selection of mutations during beta-lactam therapy, or from the direct acquisition of infections by AmpC-producing mutants. Here we report on the structural and functional biology of potential drug targets within the Gram-negative PG recycling pathway and the utility of blocking PG recycling as a means of attenuating AmpC-mediated resistance in P. aeruginosa.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据